Premium
Reduction in bradykinin generation during leukocytapheresis using novel cellsorba TM CS‐180S: Effects of changing the filling solution
Author(s) -
Yamada Risa,
Kusaoi Makio,
Murayama Go,
Yasui Misa,
Hishinuma Ruka,
Nemoto Takuya,
Hohtatsu Katsura,
Kageyama Michiaki,
Kawamoto Toshio,
Sugimoto Kaoru,
Sekiya Fumio,
Kon Takayuki,
Ogasawara Michihiro,
Kempe Kazuo,
Yamaji Ken,
Tsuda Hiroshi,
Takasaki Yoshinari
Publication year - 2014
Publication title -
journal of clinical apheresis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.697
H-Index - 46
eISSN - 1098-1101
pISSN - 0733-2459
DOI - 10.1002/jca.21297
Subject(s) - bradykinin , medicine , adverse effect , rheumatoid arthritis , receptor
We evaluated the bradykinin generation level during leukocytapheresis (LCAP) using novel Cellsorba TM CS‐180S, which has sodium pyrosulfite and sodium carbonate as a filling solution. Subjects of this study were 14 rheumatoid arthritis patients. Regardless of the type of anticoagulant used, bradykinin levels were lower with the novel CS‐180S than with the conventional CS‐180S (28.7 ± 53.3 vs. 8.0 ± 2.7 as the mean ± standard deviation). When anticoagulants other than nafamostat mesilate were used with the conventional CS‐180S, bradykinin levels increased at the column outlet compared with the column inlet, and adverse effects of bradykinin were seen in several cases. In contrast, bradykinin levels remained low and no bradykinin‐associated adverse events were observed with the novel CS‐180S. We recommend using the novel column instead of the conventional column in the treatment of LCAP. J. Clin. Apheresis 29:90–96, 2014. © 2013 Wiley Periodicals, Inc.